It has been shown that site-specific phosphorylation of tau at threonine 205 (T205) by the kinase p38γ disengages tau from toxic pathways, thus acting as a neuroprotective function in Alzheimer’s disease. Researchers in Australia have designed a novel AAV-based gene therapy approach targeting p38γ, DBA/2.p38γCA, in murine models of epilepsy in which tau is known to play a neurotoxic effect.
The sigma 1 receptor is widely distributed in the nervous system and its function has been implicated in a number of neurological disorders including dementia, Alzheimer’s disease (AD) and other neurodegenerative diseases. In a recent publication, researchers from the University of Nebraska detailed the discovery of novel sigma 1 receptor modulators.
Skynor Medical (Shanghai) Co. Ltd. has raised ¥100 million (US$15 million) in a financing round to step up its efforts in product development and market expansion. More specifically, the Shanghai-based company intends to use the funds to develop its interventional treatment solutions for neuro and peripheral vascular diseases, as well as expand them to markets at home and abroad.
Recent news from Quralis Corp. and Xenon Pharmaceuticals Inc. highlighted the potential for targeting the Kv7 potassium channel, of special interest to a handful of developers lately.
Johns Hopkins University has described prodrugs of sphingomyelin phosphodiesterase 3 (SMPD3; nSMase2) inhibitors reported to be useful for the treatment of cancer, neurological disorders, infections and inflammatory disorders.
Shanghai Raising Pharmaceutical Co. Ltd. has disclosed pyrimidines acting as amyloid-β (Aβ) protein production inhibitors reported to be useful for the treatment of Alzheimer's disease.
Ventus Therapeutics Inc. has nominated a potential first-in-class cyclic GMP-AMP synthase (cGAS) inhibitor, VENT-03, as the company’s first development candidate directed against cGAS.
A model of tauopathy developed in the worm nematode Caenorhabditis elegans was developed for investigating the mechanisms behind tauopathy development.
Eli Lilly and Co., through its wholly owned subsidiary Prevail Therapeutics Inc., is delving more deeply into gene therapies. In a new collaboration, Prevail will use privately held Capsida Biotherapeutics Inc.’s adeno-associated virus engineering platform, coupling the tech with Prevail’s gene therapies to target causes of CNS diseases.
RSS
